Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 2/20 | 0.75 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.75 |
| ▸ | STS | P08842 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.71 |
| ▸ | ESR1 | P03372 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.67 |
| ▸ | ATM | Q13315 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 2/20 | 0.67 |
| ▸ | AR | P10275 | 2/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 2/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4395104 | 1.00 | ABCC4 (0.75) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL4382857 | 0.89 | ABCC4 (0.80) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL6364570 | 0.89 | ABCC4 (0.80) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL15942368 | 0.89 | ABCC4 (0.70) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL6364269 | 0.88 | USP2 (0.63) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL3370188 | 0.88 | USP2 (0.63) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL30471686 | 0.86 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL232797 | 0.86 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL29392632 | 0.86 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA | |
| SCHEMBL232796 | 0.86 | ABCC4 (1.00) | ABCC4ABCC1STSKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0775156-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRA-1,3,5(10)-TRIENE DERIVATIVES | JENAPHARM GMBH (DE) | 2003-09-03 | — | — | EP | claimed |
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | STERIX LIMITED (GB) | 2002-05-23 | — | — | US | claimed |
| US-6841548-B2 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | SCHERING AG (DE) | 2005-01-11 | — | — | US | disclosed |
| EP-0775156-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRA-1,3,5(10)-TRIENE DERIVATIVES | JENAPHARM GMBH (DE) | 2003-09-03 | — | — | EP | disclosed |
| US-6569844-B1 | Hormonal contraception and hormon replacement therapy with low hepatic estrogenity | JENAPHARM GMBH & CO., KG (DE) | 2003-05-27 | — | — | US | disclosed |
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | STERIX LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061868-A1 | Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives | ESRRA, ESR2, CYP19A1 | ABCC4 2078/4885ABCC1 819/4885STS 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.